7 results on '"Kawaguchi, Kei"'
Search Results
2. [Reconstruction of Portal Vein and Superior Mesenteric Vein Using Superficial Femoral Vein Graft in Surgical Resection of Pancreatic Head Cancer-A Case Report].
- Author
-
Umino Y, Mizuma M, Akamatsu D, Aoki S, Iseki M, Kawaguchi K, Masuda K, Ishida M, Ohtsuka H, Nakagawa K, Morikawa T, Kamei T, Kume K, Masamune A, and Unno M
- Subjects
- Femoral Vein, Humans, Male, Middle Aged, Pancreaticoduodenectomy, Portal Vein surgery, Mesenteric Veins surgery, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms surgery
- Abstract
We report a case of reconstruction of the portal vein(PV)and superior mesenteric vein(SMV)using a superficial femoral vein graft in total pancreatectomy for pancreatic cancer. A 62-year-old man visited a previous hospital due to epigastric pain and bilirubinuria and was diagnosed with pancreatic cancer. The patient was referred to our hospital for further examination and treatment. Abdominal CT scan revealed a 30 mm pancreatic head tumor with an abutment of almost 360 degrees around the superior mesenteric artery(SMA)and extensive involvement from the PV to branches of the SMV, radiologically classified as locally advanced unresectable pancreatic cancer. Although gemcitabine plus nab-paclitaxel combination therapy(GnP)was performed, the patient developed drug-induced lung injury after 3 courses. GnP was stopped, and chemoradiation therapy with S-1 was performed. After chemoradiation therapy, the tumor shrank to 14 mm, while no change of the abutment around SMA was observed. After 8 months from the initial diagnosis, total pancreatectomy and resection of the PV/SMV were performed. Approximately 70 mm of the PV/SMV was surgically removed and was reconstructed using a graft from the left superficial femoral vein in consideration of the length and diameter. Although delayed gastric emptying was postoperatively observed, the patient was discharged 39 days after operation, then received adjuvant therapy with S-1. The patient is alive without recurrence and the patency of PV/SMV was well maintained.
- Published
- 2021
3. [A Successful Case of Pancreaticoduodenectomy after Neoadjuvant Therapy for Pancreatic Head Cancer with Acute Pancreatitis Due to Iatrogenic Injury of the Pancreatic Duct].
- Author
-
Chiba K, Mizuma M, Motoi F, Hayashi H, Aoki S, Hata T, Takadate T, Kawaguchi K, Masuda K, Ishida M, Ohtsuka H, Nakagawa K, Morikawa T, Kamei T, and Unno M
- Subjects
- Acute Disease, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Iatrogenic Disease, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Pancreatic Ducts, Pancreaticoduodenectomy, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms surgery, Pancreatitis
- Abstract
A 64-year-old woman was referred to our hospital for treatment of pancreatic head cancer with acute pancreatitis due to iatrogenic injury of the pancreatic duct during endoscopic retrograde cholangiopancreatography. In addition to a 28 mm pancreatic head tumor, soft tissue shadow and fluid collection surrounding the superior mesenteric artery(SMA)due to pancreatitis were observed in the abdominal CT scan. The tumor was histologically diagnosed as adenocarcinoma by endoscopic ultrasound-guided fine needle aspiration. Neoadjuvant chemotherapy with gemcitabine and S-1 was performed to control the progression of the pancreatic cancer and improve the inflammatory changes for reduction of the operative risk. After 2 courses of neoadjuvant chemotherapy, abdominal CT scan revealed stable disease according to the Response Evaluation Criteria in Solid Tumors and attenuation of the inflammatory changes surrounding the SMA. Then, subtotal stomach- preserving pancreaticoduodenectomy was performed without the difficulty of peeling around the SMA in spite of the old inflammatory changes. Histological examination of the resected specimen showed R0 resection. The patient was discharged 18 days after surgery without any complications and is surviving 9 months postoperatively without any recurrence. Neoadjuvant chemotherapy was helpful for disease control and improvement of the inflammatory changes.
- Published
- 2021
4. [Conversion Surgery for Locally Advanced Unresectable Pancreatic Cancer Treated with FOLFIRINOX Therapy and Proton Beam Therapy Combined with S-1 Chemotherapy-A Case Report].
- Author
-
Umino Y, Mizuma M, Iseki M, Hata T, Takadate T, Kawaguchi K, Aoki T, Motoi F, Naito T, Kamei T, Masamune A, Ishioka C, Ono T, Murakami M, and Unno M
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Japan, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Pancreatectomy, Pancreatic Neoplasms therapy, Proton Therapy
- Abstract
We report a case of locally advanced unresectable(UR-LA)pancreatic cancer in a patient who underwent conversion surgery after FOLFIRINOX and proton beam therapy(PBT)combined with S-1. A 68-year-old woman was referred to our hospital for a pancreatic tumor. The abdominal CT scan revealed a 40mm pancreatic body tumor with an abutment(>180°) of the celiac artery and the superior mesenteric artery. Moreover, the tumor was classified as UR-LA with a contact to the abdominal aorta. The tumor was histologically diagnosed as adenocarcinoma via an endoscopic ultrasound-guided fine-nee- dle aspiration. After 2 courses of FOLFIRINOX, PBT(50 GyE/25 Fr)combined with S-1 were administered. The tumor shrunk to 30mm at the CT scan. After 5 courses of FOLFIRINOX, the tumor reduced to 20 mm. No distant metastasis or malignant cells in abdominal washing cytology was detected using staging laparoscopy. Then, distal pancreatectomy with celiac axis resection(DP-CAR)was performed. According to the General Rules for the Study of Pancreatic Cancer(7th edition)from Japan Pancreas Society, the histological findings were suggestive of ypT3, ypN0, R0, and Grade 3 histological effect. The patient had a Grade A delayed gastric emptying post-operation. He was discharged 35 days after the surgery and has been alive without recurrence on imaging for 11 months post-operation.
- Published
- 2019
5. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery].
- Author
-
Taniguchi H, Mizuma M, Motoi F, Abe T, Okada R, Kawaguchi K, Karasawa H, Masuda K, Yabuuchi S, Fukase K, Sakata N, Okada T, Nakagawa K, Hayashi H, Morikawa T, Yoshida H, Naito T, Katayose Y, Egawa S, and Unno M
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma surgery, Chemotherapy, Adjuvant, Deoxycytidine therapeutic use, Fatal Outcome, Female, Humans, Liver Neoplasms drug therapy, Middle Aged, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms surgery, Pancreaticoduodenectomy, Recurrence, Time Factors, Gemcitabine, Adenocarcinoma secondary, Antimetabolites, Antineoplastic therapeutic use, Deoxycytidine analogs & derivatives, Liver Neoplasms secondary, Pancreatic Neoplasms pathology
- Abstract
Here we report a rare case of late recurrence of pancreatic cancer 8 years after surgery. A woman in her mid-fifties was hospitalized for examination of epigastralgia. Computed tomography (CT) revealed a 4 cm nodule at the pancreatic head with suspected invasion of the superior mesenteric vein. She underwent pancreaticoduodenectomy with wedge resection of superior mesenteric vein and intraoperative radiation therapy. Pathological findings showed moderately differentiated tubular adenocarcinoma and T3N1M0, Stage IIB according to The Union for International Cancer Control (UICC) TNM classification. As adjuvant chemotherapy, 56 courses of gemcitabine (GEM) were administered in 3.5 years. Because of long-term use of GEM, common terminology criteria for adverse events (CTCAE) Grade 3 anemia occurred, and chemotherapy was discontinued. Tumor markers were evaluated every month and CT scans were taken every 6 months for 5 years. Subsequently, CT was performed annually. The patient was hospitalized for high-grade fever, 8.5 years after surgery. CT, magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) detected local recurrence with liver metastases. GEM was administered again, but was ineffective. The patient died 9 years after surgery. In conclusion, even if long-term survival is achieved in pancreatic cancer, follow-ups should not be stopped.
- Published
- 2014
6. [A case of curatively resected locally advanced pancreatic cancer with combined resection of the portal vein and common hepatic artery after neoadjuvant chemotherapy].
- Author
-
Kawaguchi K, Motoi F, Yokoyama S, Takemura S, Doi T, Nozawa Y, Fujishima F, Unno M, and Kuroda F
- Subjects
- Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Drug Combinations, Humans, Male, Neoplasm Staging, Oxonic Acid administration & dosage, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Pancreaticoduodenectomy, Tegafur administration & dosage, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hepatic Artery surgery, Neoadjuvant Therapy, Pancreatic Neoplasms surgery, Portal Vein surgery
- Abstract
A man in his 40s had a locally advanced pancreatic head cancer invading the portal vein( PV) and common hepatic artery (CHA). He underwent 5 courses of neoadjuvant chemotherapy( gemcitabine+S-1), which reduced the tumor volume and cancer antigen 19-9 (CA19-9) level. R0 resection was performed via sub-stomach preserving pancreatoduodenectomy with combined resection of the PV and CHA. Adjuvant chemotherapy with gemcitabine was administered at 4 weeks after the operation. Relevant neoadjuvant chemotherapy is considered to contribute to R0 resection of locally advanced pancreatic cancer. Here, we report a case of a successful R0 resection after neoadjuvant chemotherapy for locally advanced pancreatic cancer.
- Published
- 2013
7. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
- Author
-
Motoi F, Kawaguchi K, Aoki T, Kudo K, Yabuuchi S, Fukase K, Mizuma M, Sakata N, Otsutomo S, Morikawa T, Hayashi H, Nakagawa K, Okada T, Yoshida H, Naitoh T, Katayose Y, Egawa S, and Unno M
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Male, Middle Aged, Neoplasm Invasiveness, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery, Retrospective Studies, Risk Factors, Pancreatic Neoplasms, Neoadjuvant Therapy, Pancreatic Neoplasms drug therapy
- Abstract
Surgery followed by adjuvant chemotherapy is standard care for resectable pancreatic carcinoma. The maximum estimated 2-year survival rate associated with this strategy is nearly 50%. The use of neoadjuvant therapy for pancreatic cancer remains controversial, and its efficacy has not been elucidated. To evaluate the efficacy of neoadjuvant chemotherapy for planned pancreatic cancer resection, the oncological outcomes of neoadjuvant gemcitabine plus S-1 combination therapy( GS therapy) and a surgery-first approach were retrospectively compared. Patients with planned pancreatic cancer resection and without major artery abutments were enrolled in this study. There were 39 cases of neoadjuvant GS therapy (N group) and 93 cases of the surgery-first approach( S group). Survival and surrogate markers, including the R0 rate, the "true R0 rate"( R0 with tumor marker normalization after resection), and N0 rate, were compared. The groups did not differ significantly in terms of age, gender, or tumor location. The resection rates of the N and S groups were similar (92% and 86%, respectively). The median survival of the N group (39.4 months) was significantly longer than that of the S group (20.8 months) in intention-to-treat analysis (p=0.0009). The R0, true R0, and N0 rates of the N group (85%, 69%, and 44%, respectively) were higher than those of the S group( 72%, 48%, and 24%, respectively). In conclusion, this retrospective analysis showed that neoadjuvant GS therapy might be more effective than the standard surgery-first strategy in terms of oncological outcomes for resectable pancreatic cancer. A prospective randomized study, Prep-02/JSAP-05, which compares neoadjuvant therapy to the surgery-first approach, is ongoing (UMIN-No. 000009634).
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.